Drug profile · INN
fedratinib
INREBIC
fedratinib (INREBIC) is a tyrosine-protein kinase jak2 inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01EJ02
Patents linked 0
Pipeline programs 3
News articles 0
Drug details — fedratinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 3
- Data quality
- 0.83
Quick answer
fedratinib (INREBIC) is a tyrosine-protein kinase jak2 inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd.
Key facts
INN fedratinib
Brand INREBIC
Mechanism Tyrosine-protein kinase JAK2 inhibitor
Target Tyrosine-protein kinase JAK2
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EJ02
Originator Bristol-Myers Squibb Australia Pty Ltd
Mechanism of action
Tyrosine-protein kinase JAK2 inhibitor
Primary target: Tyrosine-protein kinase JAK2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is fedratinib?
fedratinib (INREBIC) is a tyrosine-protein kinase jak2 inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd.
What is the brand name for fedratinib?
INREBIC is a marketed brand name for fedratinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.